Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); 2012 Preview: Cautious in Front of Pimavanserin Phase 3 Results Expected in 3Q12
Go back to Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); 2012 Preview: Cautious in Front of Pimavanserin Phase 3 Results Expected in 3Q12| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 28.24 -0.14 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.38 | 52 Week High | $42.49 | |||
| Open | $28.26 | 52 Week Low | $16.64 | |||
| Day High | $28.43 | P/E | N/A | |||
| Day Low | $27.90 | EPS | $-0.42 | |||
| Volume | 1,062,579 | |||||
